Clearside Biomedical, Inc. to Present at the 2016 Ladenburg Thalmann Healthcare Conference
September 20, 2016 16:30 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Reports Second Quarter 2016 Financial Results
August 11, 2016 07:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference
August 10, 2016 07:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. to Report Second Quarter 2016 Financial Results
August 04, 2016 07:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. to Present Data from Phase 2 (DOGWOOD) Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis at the 2016 ASRS Annual Meeting
August 03, 2016 07:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces Promotion of Glenn Noronha, Ph.D. to Chief Scientific Officer and Jennifer M. Kissner, Ph.D. to Vice President, Clinical Development
August 01, 2016 07:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
Clearside Biomedical, Inc. Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
July 26, 2016 07:30 ET
|
Clearside Biomedical, Inc.
78% of Patients Required No Additional Treatment in the Trial Arm with Concomitant Suprachoroidally Administered Zuprata™ and Intravitreally Administered Eylea®Patients Reached an Average BCVA...
Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering
June 01, 2016 23:15 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., June 01, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...